Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Corrélation précoce de la TEP/TDM au FDG et de l'ADNct chez les patients atteints de mélanome traités par un inhibiteur de point de contrôle immunitaire (ICI)

11 novembre 2026 mis à jour par: University of Wisconsin, Madison

Corrélation entre la tomographie/tomographie par émission de positrons de 18F-fluorodésoxyglucose à intervalle précoce (TEP/CT) et l'ADN tumoral circulant (ADNc) chez les patients atteints de mélanome avancé traités avec des inhibiteurs de point de contrôle immunitaire

The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.

Primary Objective

• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.

Secondary Objectives

  • To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.

Type d'étude

Observationnel

Inscription (Réel)

25

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Wisconsin
      • Madison, Wisconsin, États-Unis, 53792
        • University of Wisconsin Hospitals and Clinics (UWHC)

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.

La description

Inclusion Criteria:

  • Willing to provide informed consent.
  • Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
  • Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
  • Individuals at least 18 years of age.
  • Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
  • Willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

  • Not able to receive treatment with ICI therapy
  • Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
  • Women who are pregnant, lactating, or planning on becoming pregnant during the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Patients atteints de mélanome avancé avec inhibiteurs de points de contrôle immunitaires

research scan 3-4 weeks after start of immunotherapy

Autres noms:
  • 18F-FDG TEP/TDM

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Délai: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

ctDNA level is monitored per standard of care in this population, data from chart review.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Délai: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Délai: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Délai: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve).

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective Response Rate (ORR)
Délai: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR).

up to 12 months after the first ICI dose (approximately 1 year on study)
Disease Control Rate (DCR)
Délai: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR.

up to 12 months after the first ICI dose (approximately 1 year on study)
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Délai: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0

up to 12 months after the first ICI dose (approximately 1 year on study)
Progression Free Survival (PFS)
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Overall Survival (OS)
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Délai: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Vincent Ma, MD, University of Wisconsin, Madison

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 janvier 2024

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

1 janvier 2029

Dates d'inscription aux études

Première soumission

27 décembre 2023

Première soumission répondant aux critères de contrôle qualité

27 décembre 2023

Première publication (Réel)

10 janvier 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 janvier 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2023-1089
  • A534260 (Autre identifiant: UW Madison)
  • UW23077 (Autre identifiant: UWCCC)
  • Protocol Version 2/12/2024 (Autre identifiant: UW Madison)
  • NCI-2023-11059 (Identificateur de registre: NCI Trial ID)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .